SSI Strategy Holdings LLC

SSI Strategy Holdings LLC is a specialized consultancy focused on providing tailored support services for the biotech sector, aiding companies in transforming innovative ideas into market-ready products. Founded in 2010 and headquartered in Parsippany-Troy Hills, US, SSI Strategy Holdings LLC specializes in strategic advisory and operational support for the biotech industry. The company has engaged in a singular significant deal, with the latest occurring on December 21, 2020. The firm was established by Gregory Fiore, who has a history of founding other companies, and is currently led by CEO Douglas Locke.

SSI Strategy provides comprehensive support services tailored to the biotech sector, focusing on transforming innovative ideas into viable products. Their core offerings encompass strategic advisory, regulatory guidance, and operational excellence across various stages of drug development, from pre-clinical through to market launch. The multidisciplinary team engages in activities such as ensuring scientific integrity, facilitating patient-centric clinical development, and generating strategic evidence to optimize regulatory approval processes. Their clientele includes biotech firms, ranging from start-ups with single-molecule developments to established entities seeking to enhance their product portfolios globally, serving diverse markets including North America, Europe, and select regions in Asia.

The revenue model of SSI Strategy is structured around B2B partnerships, where clients engage the firm for specialized advisory services and operational support throughout the drug development lifecycle. Business transactions typically involve retainer agreements or project-based pricing, allowing clients to access tailored services that meet their specific needs. Revenue is generated through a combination of fixed project fees and ongoing advisory retainers, supported by the firm's focus on building long-term relationships with biotech firms. Following a strategic investment by Amulet Capital Partners on December 21, 2020, the funds will be utilized to accelerate growth and expand strategic services supporting Medical, Clinical, and other critical path functions at the C-level of Life Sciences companies.

SSI Strategy aims to launch new products designed to support biotech firms more effectively and plans to expand its market reach into additional regions, specifically targeting markets in Europe and Asia by 2023.